Angiographic and clinical performance of polymer‐free biolimus‐eluting stent in patients with ST‐segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study. Issue 5 (2nd August 2017)

• Record Type: Journal Article
• Authors: Sgueglia, Gregory A.; D'Errico, Fabrizio; Gioffrè, Gaetano; De Santis, Antonella; Summaria, Francesco; Piccioni, Fabiana; Gaspardone, Achille
• Is Part Of: Catheterization and cardiovascular interventions. Volume 91:Issue 5(2018)
• Page Start: 851
• Page End: 858
• Publication Date: 2017-08-02
• Subjects: acute myocardial infarction -- biolimus -- drug‐coated stent -- percutaneous coronary intervention -- polymer‐free -- primary angioplasty; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27206
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: This study aimed at assessing the performance of a new generation polymer‐free biolimus‐eluting stent (BES) in real‐world patients with ST‐segment elevation myocardial infarction (STEMI). Background: Polymers components of early‐generation drug‐eluting stents have been implicated in the pathogenesis of delayed arterial healing, vessel remodeling, and delayed stent thrombosis. Recently, a novel polymer‐free BES has shown excellent clinical performance in clinical trial setting. Methods: Overall, 175 consecutive patients (64 ± 14 years, 141 men) treated with the BioFreedom (Biosensors Europe, Morges, Switzerland) polymer‐free BES because of STEMI were included in this study. The primary endpoint was the rate of major adverse cardiac events (MACE), a composite of cardiac death, recurrent myocardial infarction, and ischemia‐driven target vessel revascularization at 1 year follow‐up. A subgroup of patients underwent 6‐month angiographic follow‐up. Dual antiplatelet therapy was prescribed for 12 months after STEMI. Results: At 1 year, the cumulative rate of MACE was 4.6%. One patient (0.6%) had an arrhythmic cardiac death and five (2.9%) had ischemia‐driven target vessel revascularization, although only three (1.7%) had target lesion revascularization. Two (1.1%) patients had acute stent thrombosis yielding nonfatal myocardial infarction. In 70 patients (63 ± 14 years, 61 men), quantitative coronary angiography at 6‐month follow‐up revealed diameter stenosis of 24.1 ± 13.7% and minimal lumen diameter of 2.29 ± 0.56 mm, yielding a late lumen loss of 0.13 ± 0.14 mm. Conclusions: In real‐world setting, implantation of a new‐generation polymer‐free BES during STEMI is associated with favorable clinical and angiographic results, pointing toward the overall efficacy and safety of the device in complex clinical scenarios.